Xue‐Ru Wu

14.3k total citations · 2 hit papers
208 papers, 10.9k citations indexed

About

Xue‐Ru Wu is a scholar working on Molecular Biology, Surgery and Urology. According to data from OpenAlex, Xue‐Ru Wu has authored 208 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Molecular Biology, 89 papers in Surgery and 40 papers in Urology. Recurrent topics in Xue‐Ru Wu's work include Bladder and Urothelial Cancer Treatments (74 papers), Urological Disorders and Treatments (33 papers) and Epigenetics and DNA Methylation (33 papers). Xue‐Ru Wu is often cited by papers focused on Bladder and Urothelial Cancer Treatments (74 papers), Urological Disorders and Treatments (33 papers) and Epigenetics and DNA Methylation (33 papers). Xue‐Ru Wu collaborates with scholars based in United States, China and Switzerland. Xue‐Ru Wu's co-authors include Tung‐Tien Sun, Ellen Shapiro, Tarek M. El‐Achkar, David L. Hasty, Juan J. Martínez Medina, Lan Mo, Herbert Lepor, Feng‐Xia Liang, Xiang‐Peng Kong and Hong-Ying Huang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Xue‐Ru Wu

203 papers receiving 10.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Urothelial tumorigenesis: a tale of divergent pathways

2005 529 citations Xue‐Ru Wu profile →
Aristolochic acid-associated urothelial cancer in Taiwan

2012 311 citations Chung‐Hsin Chen, Kathleen G. Dickman et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Xue‐Ru Wu

Since Specialization

Citations

This map shows the geographic impact of Xue‐Ru Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue‐Ru Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue‐Ru Wu more than expected).

Fields of papers citing papers by Xue‐Ru Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue‐Ru Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue‐Ru Wu. The network helps show where Xue‐Ru Wu may publish in the future.

Co-authorship network of co-authors of Xue‐Ru Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Xue‐Ru Wu. A scholar is included among the top collaborators of Xue‐Ru Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue‐Ru Wu. Xue‐Ru Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reprogramming Tumor Cell Death via Processing Natural Drug to Carbon Dots Overcomes Collagen Barrier and Activates Antitumor Immunity 2025 ·Advanced Functional Materials ·Z. R. Yan, Hongwei Cheng, Yupeng Liu, Wenfeng Xu, Quansheng Cheng, Lingyun Li, Xue‐Ru Wu, (unknown), Jing Zhao, Gang Liu, Shao-Ping Li, Songnan Qu	1
2	Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis 2025 ·Radiation Oncology ·Mingfeng He, Xue‐Ru Wu, Li Li, (unknown), Yitian Wang, (unknown), Ying Ye, (unknown), Zaicheng Xu, Zhenzhou Yang	2
3	The kidney protects against sepsis by producing systemic uromodulin 2022 ·American Journal of Physiology-Renal Physiology ·Kaice A. LaFavers, Chadi A. Hage, (unknown), Radmila Micanovic, Takashi Hato, Shehnaz Khan, Seth Winfree, Simit Doshi, Ranjani N. Moorthi, Homer L. Twigg, Xue‐Ru Wu, Pierre C. Dagher, Edward F. Srour, Tarek M. El‐Achkar	19
4	PKM2 Is Essential for Bladder Cancer Growth and Maintenance 2021 ·Cancer Research ·Yong Xia, Xing Wang, Yan Liu, Ellen Shapiro, Herbert Lepor, Moon‐shong Tang, Tung‐Tien Sun, Xue‐Ru Wu	43
5	CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target 2020 ·Cancer Communications ·Wen Zhang, Huishan Wang, (unknown), Xueting Deng, Xue‐Ru Wu, Yilan Ma, Mengjing Li, (unknown), Qiang You, Lin Miao	151
6	Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice 2019 ·Proceedings of the National Academy of Sciences ·Moon‐shong Tang, Xue‐Ru Wu, Hyun‐Wook Lee, Yong Xia, Fang‐Ming Deng, André L. Moreira, Lung‐Chi Chen, William C. Huang, Herbert Lepor	149
7	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum 2016 ·Molecular Cancer Therapeutics ·Zhongbo Liu, Noriko Yokoyama, Christopher Blair, Xuesen Li, Daina Avizonis, Xue‐Ru Wu, Edward Uchio, Ramy F. Youssef, Michael McClelland, Michaël Pollak, Xiaolin Zi	13
8	Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53 -Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas 2015 ·Cancer Research ·Feng He, Jonathan Melamed, Moon‐shong Tang, Chuanshu Huang, Xue‐Ru Wu	25
9	Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo 2015 ·Cancer Prevention Research ·Venkateshwar Madka, Altaf Mohammed, Qian Li, Yuting Zhang, Laura Biddick, Jagan M.R. Patlolla, Stan Lightfoot, Rheal A. Towner, Xue‐Ru Wu, Vernon E. Steele, Levy Kopelovich, Chinthalapally V. Rao	13
10	ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms 2015 ·Cancer Research ·Phillip L. Palmbos, Lidong Wang, Huibin Yang, Yin Wang, (unknown), (unknown), John E. Wilkinson, Chandan Kumar‐Sinha, Gina M. Ney, Scott A. Tomlins, Stephanie Daignault, Lakshmi P. Kunju, Xue‐Ru Wu, Yair Lotan, Monica Liebert, Mats Ljungman, Diane M. Simeone	60
11	SU‐E‐J‐244: Development and Validation of a Knowledge Based Planning Model for External Beam Radiation Therapy of Locally Advanced Non‐Small Cell Lung Cancer 2015 ·Medical Physics ·(unknown), Erik Larsen, (unknown), (unknown), (unknown), (unknown), C W Hayes, (unknown), (unknown), Xue‐Ru Wu, (unknown), Andrew S. Kennedy	1
12	KAVA Chalcone, Flavokawain A, Inhibits Urothelial Tumorigenesis in the UPII-SV40T Transgenic Mouse Model 2013 ·Cancer Prevention Research ·Zhongbo Liu, Xia Xu, Xuesen Li, Shuman Liu, Anne R. Simoneau, Feng He, Xue‐Ru Wu, Xiaolin Zi	30
13	Decreased Tumorigenesis and Mortality from Bladder Cancer in Mice Lacking Urothelial Androgen Receptor 2013 ·American Journal Of Pathology ·(unknown), Iawen Hsu, Defeng Xu, Hiroshi Miyamoto, Liang Liang, Xue‐Ru Wu, Chih-Rong Shyr, Chawnshang Chang	99
14	Aristolochic acid-associated urothelial cancer in Taiwan breakdown → 2012 ·Proceedings of the National Academy of Sciences ·Chung‐Hsin Chen, Kathleen G. Dickman, Masaaki Moriya, Jiří Zavadil, Viktoriya S. Sidorenko, Karen L. Edwards, Dmitri V. Gnatenko, Lin Wu, Robert J. Turesky, Xue‐Ru Wu, Yeong‐Shiau Pu, Arthur P. Grollman	311
15	Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies 2012 ·Carcinogenesis ·Hong‐Hao Zhou, Weiwei Huang, Ellen Shapiro, Herbert Lepor, William C. Huang, Moosa Mohammadi, Ian Mohr, (unknown), Chuanshu Huang, Xue‐Ru Wu	17
16	Temporally and spatially controllable gene expression and knockout in mouse urothelium 2010 ·American Journal of Physiology-Renal Physiology ·Haiping Zhou, Yan Liu, Feng He, Lan Mo, Tung‐Tien Sun, Xue‐Ru Wu	12
17	Deficiency of pRb Family Proteins and p53 in Invasive Urothelial Tumorigenesis 2009 ·Cancer Research ·Feng He, Lan Mo, Xiaoyong Zheng, Changkun Hu, Herbert Lepor, (unknown), Tung‐Tien Sun, Xue‐Ru Wu	63
18	Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression 2008 ·American Journal of Physiology-Renal Physiology ·Tarek M. El‐Achkar, Xue‐Ru Wu, Michael Rauchman, Ruth McCracken, Susan M. Kiefer, Pierre C. Dagher	139
19	Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis 2007 ·Journal of Clinical Investigation ·Lan Mo, Xiaoyong Zheng, Hong-Ying Huang, Ellen Shapiro, Herbert Lepor, Carlos Cordon‐Cardo, Tung‐Tien Sun, Xue‐Ru Wu	89
20	A Survivin Gene Signature Predicts Aggressive Tumor Behavior 2005 ·Cancer Research ·Whitney Salz, Dan Eisenberg, Janet Plescia, David S. Garlick, Robert M. Weiss, Xue‐Ru Wu, Tung‐Tien Sun, Dario C. Altieri	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact